Women’s Health Bulletin

Published by: Kowsar

The Effect of Magnesium Oxide on Hyperphosphatemia in Female Hemodialysis Patients

Maryam Pakfetrat 1 , Shokouh Sharifpour 2 , Leila Malekmakan 3 , * , Shahrokh Ezzatzadegan Jahromi 1 , Jamshid Roozbeh 1 and Amir Aslani 4
Authors Information
1 Department of Internal Medicine, Shiraz Nephro Urology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Shiraz Nephro Urology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Department of Community Medicine, Shiraz Nephro Urology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Women's Health Bulletin: June 16, 2014, 1 (2); e20048
  • Published Online: June 11, 2014
  • Article Type: Research Article
  • Received: March 17, 2014
  • Revised: April 2, 2014
  • Accepted: May 10, 2014
  • DOI: 10.17795/whb-20048

To Cite: Pakfetrat M, Sharifpour S, Malekmakan L, Ezzatzadegan Jahromi S, Roozbeh J, et al. The Effect of Magnesium Oxide on Hyperphosphatemia in Female Hemodialysis Patients, Women Health Bull. 2014 ; 1(2):e20048. doi: 10.17795/whb-20048.

Copyright © 2014, Health Policy Research Center, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Pendse S, Singh A. Handbook of dialysis. 2007; : 8
  • 2. Daugirdas J. Handbook of dialysis. 2007; : 168
  • 3. Coyne D, Cheng S, Delmez JA. Handbook of dialysis. 2007; : 589-91
  • 4. Kanbay M, Goldsmith D, Uyar ME, Turgut F, Covic A. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif. 2010; 29(3): 280-92[DOI][PubMed]
  • 5. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996; 49(1): 163-7[PubMed]
  • 6. Fournier A, Moriniere P. Magnesium hydroxide is a useful complementary aluminum-free phosphate binder to moderate doses of oral calcium in uremic patients on chronic hemodialysis. Clin Nephrol. 1988; 29(6): 319[PubMed]
  • 7. Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. Magnes Res. 2001; 14(4): 257-62[PubMed]
  • 8. Kuhlmann MK. Management of hyperphosphatemia. Hemodial Int. 2006; 10(4): 338-45[DOI][PubMed]
  • 9. Ketteler M. Phosphorus Control in Chronic Kidney Disease. Eur Ren Genitourin Dis. 2007; 1(24): 18-21
  • 10. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009; 20(2): 388-96[DOI][PubMed]
  • 11. Tzanakis IP, Papadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol. 2008; 40(1): 193-201[DOI][PubMed]
  • 12. Vetter T, Lohse MJ. Magnesium and the parathyroid. Curr Opin Nephrol Hypertens. 2002; 11(4): 403-10[PubMed]
  • 13. Spiegel DM, Farmer B, Smits G, Chonchol M. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr. 2007; 17(6): 416-22[DOI][PubMed]
  • 14. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010; 25(11): 3707-17[DOI][PubMed]
  • 15. O'Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet. 1986; 1(8486): 880-2[PubMed]
  • 16. Deuber HJ. Long-term efficacy and safety of an oral phosphate binder containing both calcium acetate and magnesium carbonate in hemodialysis patients. Nieren-und Hochdruckkrankheiten. 2004; 33(8): 403–8[DOI]
  • 17. Parsons V, Papapoulos SE, Weston MJ, Tomlinson S, O'Riordan JL. The long-term effect of lowering dialysate magnesium on circulating parathyroid hormone in patients on regular haemodialysis therapy. Acta Endocrinol (Copenh). 1980; 93(4): 455-60[PubMed]
  • 18. Agus ZS, Morad M. Modulation of cardiac ion channels by magnesium. Annu Rev Physiol. 1991; 53: 299-307[DOI][PubMed]
  • 19. Moriniere P, Vinatier I, Westeel PF, Cohemsolal M, Belbrik S, Abdulmassih Z, et al. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant. 1988; 3(5): 651-6[PubMed]
  • 20. Guillot AP, Hood VL, Runge CF, Gennari FJ. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron. 1982; 30(2): 114-7[PubMed]
  • 21. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol. 2005; 16 Suppl 2-14[DOI][PubMed]
  • 22. Oe PL, Lips P, van der Meulen J, de Vries PM, van Bronswijk H, Donker AJ. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol. 1987; 28(4): 180-5[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments